Evidence map›Paper›PMID 30090004›Full record

ReviewWorld journal of gastroenterology2018

Rethinking

Isabel Aguilera, Elena Aguado-Dominguez, Jose Manuel Sousa, Antonio Nuñez-Roldan

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Isabel AguileraDepartment of Immunology, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Sevilla 41013, Spain. iaguilera-ibis@us.es.
Elena Aguado-DominguezDepartment of Immunology, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Sevilla 41013, Spain.
Jose Manuel SousaDigestive and Liver Diseases Service, Hospital Universitario Virgen del Rocío, Sevilla 41013, Spain.
Antonio Nuñez-RoldanDepartment of Immunology, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Sevilla 41013, Spain.
Instituto de Biomedicina de Sevilla · ESHospital Universitario Virgen del Rocío · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-mediated rejection (AMR) in liver transplantation has long been underestimated. The concept of the liver as an organ susceptible to AMR has emerged in recent years, not only in the context of the major histocompatibility complex with the presence of HLA donor-specific antibodies, but also with antigens regarded as "minor", whose role in AMR has been demonstrated. Among them, antibodies against glutathione S-transferase T1 have been found in 100% of patients with

Indexed as

AllograftsAutoantibodiesBiopsyGlutathione TransferaseGraft RejectionHepatitis, AutoimmuneHistocompatibility AntigensHumansImmunoglobulin GLiverLiver TransplantationPlasma CellsTransplantation, HomologousAutoantibodiesglutathione S-transferase T1Glutathione TransferaseHistocompatibility AntigensImmunoglobulin GCell quantificationDe novo autoimmune hepatitisDonor-specific antibodiesGlutathione S-transferase T1 mismatchIgG4+ plasma cellLiver allograft rejectionNewCASTPlasma cell-rich rejectionT lymphocytes

Identifiers

PMID30090004
PMCPMC6079293
OpenAlexW2886874940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.